ArticleFrontiers in pharmacology2021

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50.

Qiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.